All News

pregnant-776506__180.jpg

PIANO Study - Safety of Biologics in Pregnancy

Jack Cush, MD

The results of the long awaited PIANO study have been reported in the journal Gastroenterology, showing that pregnant women with IBD may safely receive biologic or thiopurine therapy throughout the pregnancy without substantial added risk to the unborn or mother.

Read Article
Roundup RHeum ACR

Rheumatology Round-Up with Drs. Kavanaugh & Cush

Jack Cush, MD

The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!


Read Article
meeting.photo_.jpg

ACR20 - Day 2 Report

Jack Cush, MD

Saturday was the day 2 with many posters and live sessions at the 2020 Virtual ACR/ARP meeting. Here are a few of my highlights from day two:

Read Article
#BestACR20Tweets RT @ejdein1 : Draft #ACR20 Rx Recommendations for RA: MTX monotherapy conditionally rec over csDMARD dual or triple Rx, MTX+TNFi @RheumNow https://t.co/HUucJOgQgN https://t.co/xJB2zU1y2U

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @RichardPAConway Dr Lillegraven presents a randomized open-label phase 4, non-Inferiority trial of TNFi tapering in RA patients in sustained remission. 63% of tapered patients flared over 12 months vs 5% of maintained. https://t.co/JwR86kJf56 https://t.co/fFRVf6TYf9

Links:

Dr. John Cush RheumNow ( View Tweet)
TNF Inhibitor Associated Infectious Risk Greatest in First 6 Months https://t.co/fMF71rMAn8 https://t.co/mlFFb2m4UE

Links:

Dr. John Cush RheumNow ( View Tweet)
Download our 2020 TNF Inhibitor Biosimilars worksheet. https://t.co/whebbA3Ucv https://t.co/Bm5rgBPKkH

Links:

Dr. John Cush RheumNow ( View Tweet)
Download our 2020 TNF Inhibitor Biosimilars worksheet. https://t.co/whebbA3Ucv https://t.co/6t6Vu23Gmb

Links:

Dr. John Cush RheumNow ( View Tweet)
Read more on Racial disparities in Bilateral Knee Arthroplasty in Osteoarthritis by Dr. Bella Mehta ( @bella_mehta) #ACR20 https://t.co/yataL7H8X4 https://t.co/JBM8V6OX8J

Links:

Dr. John Cush RheumNow ( View Tweet)
What would you use next? sero+ RA new keratitis requiring prednisone and now also 20 SJC. New rheumatoid nodules. Pt has been on triple csDMARDs + Leflunomide, then 2 JAKi and 2 TNFi also with MTX each time. All Rx works for 6 months then relapse. @RheumNow @CRASCRRheum https://t.co/9cTS1tNE42
Janet Pope Janetbirdope ( View Tweet)
Dr Lillegraven presents a randomized open-label phase 4, non-Inferiority trial of TNFi tapering in RA patients in sustained remission. 63% of tapered patients flared over 12 months vs 5% of maintained. Good response to reintroduction of TNFi @rheumnow #ACR20 Abstr#2010 https://t.co/Ki7PTsetbH
Richard Conway RichardPAConway ( View Tweet)

Upadacitinib vs. Adalimumab vs. PBO in PsA Phase 3 RCT ⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA *⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior *⃣Similar VTE in all arms @RheumNow #ACR20 Abs#2026 https://t.co/OHzIjXKqAu

Robert B Chao, MD doctorRBC ( View Tweet)
Draft #ACR20 Rx Recommendations for RA: MTX monotherapy conditionally rec over csDMARD dual or triple Rx, MTX+TNFi @RheumNow https://t.co/jyjRD5aadN
Eric Dein ejdein1 ( View Tweet)

European Rheum Consortium (SHARE) recommendations for Rx of systemic JIA: 1) Systemic JIA - AOSD; 2) STEROIDs, 3) IL-1 inhibitors; 4) TCZ, 5) MTX & TNFi mainly for arthritis. Should be aware of risk for MAS and ILD #ACR20 Abstr#1148 https://t.co/mgZvLKNljs

Links:

Dr. John Cush RheumNow ( View Tweet)

Network Meta-Analysis of JAK and TNF Inhib in 19 AS studies (3,654pts) showed best results with TNFi (golimumab and infliximab) but JAKs also appear to be effective option. #ACR20 Abstr#1357 #UTSW @AdelaCastro222 https://t.co/HnnPD6eXW5 https://t.co/Li30kkp3P1

Links:

Dr. John Cush RheumNow ( View Tweet)

1yr results using anti-IL-23 Guselkumab shows the same ACR 20/50/70 responses regardless of prior TNF inhibitor failure. #ACR20 #Abstr#1344 https://t.co/OvgJ53wwmU https://t.co/JdajDONWap

Links:

Dr. John Cush RheumNow ( View Tweet)
For all your nr-axSpA fanatics, there's a fantastic poster on certolizumab response in nr-axSpA stratified by MRI and CRP status #ACR20 @steverheum_hall https://t.co/WI1vdMItUO https://t.co/JnvAyyClDu

Links:

Dr Philip Robinson philipcrobinson ( View Tweet)
Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients with and Without Methotrexate: Real World Results from a Rheumatoid Arthritis Cohort https://t.co/ZzhE0J7dOX #TOFA #TNFi TNFi does better with MTX Tofa less necessary

Links:

Peter Nash drpnash ( View Tweet)

Etanercept monotherapy significantly more effective than Methotrexate monotherapy in maintaining remission in RA patients on combination therapy. Data from the SEAM-RA study @RheumNow #ACR20 Abstr#0939 #ACRbest

Dr. Antoni Chan synovialjoints ( View Tweet)

After the SEAM-RA study, in patients taking MTX and ETN in sustained remission would you? #ACR20 @rheumnow

Richard Conway RichardPAConway ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×